Putting Past Elucidations to Work for the Future of Antibacterial Research
In the search for novel antibacterials, Sequoia Science acquires spectral processing and databasing software that leverages previous research to speed up the discovery process.
St. Louis, MO (August 12, 2008)—Sequoia Sciences, Inc., recently purchased and implemented powerful software from ACD/Labs that will allow them to more easily elucidate chemical structures as well as to search and validate completed elucidated structures , effectively eliminating the need to reproduce the results in the future. This will allow Sequoia to better fulfill its mandate of discovering novel antibacterial compounds from plant materials.
Sequoia Sciences creates proprietary libraries of plant products and then uses high-throughput screening (HTS) techniques against biological targets in order to identify lead compounds. Once identified, the chemical structure of the lead compound is elucidated using an array of analytical techniques. Researchers and executives at Sequoia identified a need for a set of tools that would allow them to manage all of this data effectively—from uniformity of processing, to storage and databasing of the spectra and related data.
ACD/Structure Elucidator from Advanced Chemistry Development, Inc., (ACD/Labs) fit their needs perfectly. The software includes processing and databasing modules for 1D and 2D NMR spectra, MS, UV-IR, and chromatography data. NMR prediction and verification capabilities are also included. With this suite of tools, researchers can quickly determine whether the structure of a newly screened lead compound has been elucidated in the past, or use all of the available analytical data to determine the chemical structure of an unknown.
“We see it as a major competitive advantage, to be able to take the spectrum of a hit from HTS, and compare it against the database of previously elucidated structures,” said Mark O’Neil-Johnson, VP Analytical Chemistry, Sequoia Sciences, Inc. “It gives us the ability to move that lead through the development process, much, much faster, and with far fewer resources.“
ACD/Structure Elucidator unifies analytical data from an array of techniques and vendor formats so that incompatible file formats are not an issue.
“The choice was obvious for us,” O’Neil-Johnson further comments. “The combination of search capabilities, proton and carbon chemical shift predictors as well as the structure elucidation capabilities, meant that there was no hesitation in making this investment. Our previous experience with ACD/Labs products and service made for a seamless transition in adding additional modules.”
For more information about ACD/Structure Elucidator, visit our website. www.acdlabs.com/elucidator/
About Advanced Chemistry Development
Advanced Chemistry Development, Inc., (ACD/Labs) is a chemistry software company offering solutions that truly integrate chemical structures with analytical chemistry information to produce ChemAnalytics®. ACD/Labs creates innovative software packages that aid chemical research scientists worldwide with spectroscopic validation of structures, elucidation of unknown substances, chromatographic separation, medicinal chemistry, preformulation of novel drug agents, systematic nomenclature generation, and chemical patenting and publication. Combined, ACD/Labs’ solutions create an analytical informatics system that provides dramatic feed-forward effects on the chemical and pharmaceutical research process. Founded in 1994, and headquartered in Toronto, Canada, ACD/Labs employs a team of over 145 dedicated individuals whose continual efforts carry ACD/Labs’ innovative technologies into pharmaceutical, biotech, chemical, and materials companies throughout the world. Information about Advanced Chemistry Development and its products is available at www.acdlabs.com.
About Sequoia Sciences
Founded in 2000, Sequoia Sciences has an unparalleled collection of structurally diverse natural product compounds isolated from plants. From this collection, Sequoia has identified compounds that may potentially provide alternative treatments for chronic infections involving bacterial biofilms. Based upon these results, Sequoia Sciences is embarking on a pre-clinical development program with the goal of addressing the unmet medical need for the treatment of Pseudomonas aeruginosa lung infections in Cystic Fibrosis patients. Our goal is to improve the quality of life for those individuals significantly affected by chronic bacterial infections. To this purpose, we are engaged in multiple collaborations with other laboratories and universities.
- Contact Information
- Tara Sinclair
- Media Coordinator
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.